NY-ESO-1 peptide analogs
US8354380B2 · kind B2 · utility
8Cited by
1References
45Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 2005 |
| Grant date | Jan 15, 2013 |
| Priority date | — |
| Expiry date | Feb 25, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.